Patents by Inventor Hack Woo Kim
Hack Woo Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11987833Abstract: The present invention relates to a novel enzyme capable of producing multi-hydroxy derivatives from polyunsaturated fatty acids and a method for producing multi-hydroxy derivatives of polyunsaturated fatty acids using the same.Type: GrantFiled: October 16, 2020Date of Patent: May 21, 2024Assignee: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Jeong Woo Seo, Jong Jae Yi, Sun Yeon Heo, Young Bae Kim, Chul Ho Kim, Baek Rock Oh, Jung Hyun Ju, Hack Sun Choi
-
Patent number: 11331598Abstract: Provided is a method of isolating a botulinum toxin type A macro complex from a botulinum toxin-containing solution, the method including performing anion exchange chromatography and cation exchange chromatography.Type: GrantFiled: November 29, 2017Date of Patent: May 17, 2022Assignee: MEDYTOX INC.Inventors: Hyun Ho Jung, Gi Hyeok Yang, Chang Hoon Rhee, Hack Woo Kim, Gi Hyuck Ryu, Hyung Pyo Hong, Jung Hyun Song, Joon Chan Kong
-
Publication number: 20210379165Abstract: Disclosed herein is a liquid pharmaceutical composition of botulinum toxin which is improved in stability. It comprises botulinum toxin, polysorbate 20, and methionine and optionally isoleucine. Employing, instead of the animal-derived protein albumin or gelatin, a combination of polysorbate 20 and methionine and optionally isoleucine as botulinum toxin stabilizers, the liquid pharmaceutical composition eliminates the risk of contaminating the body with serum-derived pathogens or microorganisms and can be administered safely to the body. Also, the composition is convenient for use as a direct injection for patients. Superior to conventional compositions employing either detergents or amino acids in terms of the storage stability of botulinum toxin at 25˜37° C. as well as at refrigerated temperatures, the liquid pharmaceutical composition of the present invention is very useful for storing botulinum toxin under an emergency condition such as an environment without maintaining low temperature.Type: ApplicationFiled: May 21, 2021Publication date: December 9, 2021Inventors: Hyun Ho Jung, Gi Hyeok Yang, Hack Woo Kim, Hee Dong Woo, Chang Hoon Rhee
-
Publication number: 20200009473Abstract: Provided is a method of isolating a botulinum toxin type A macro complex from a botulinum toxin-containing solution, the method including performing anion exchange chromatography and cation exchange chromatography.Type: ApplicationFiled: November 29, 2017Publication date: January 9, 2020Inventors: Hyun Ho JUNG, Gi Hyeok YANG, Chang Hoon RHEE, Hack Woo KIM, Gi Hyuck RYU, Hyung Pyo HONG, Jung Hyun SONG, Joon Chan KONG
-
Publication number: 20190298813Abstract: Disclosed herein is a liquid pharmaceutical composition of botulinum toxin which is improved in stability. It comprises botulinum toxin, polysorbate 20, and methionine and optionally isoleucine. Employing, instead of the animal-derived protein albumin or gelatin, a combination of polysorbate 20 and methionine and optionally isoleucine as botulinum toxin stabilizers, the liquid pharmaceutical composition eliminates the risk of contaminating the body with serum-derived pathogens or microorganisms and can be administered safely to the body. Also, the composition is convenient for use as a direct injection for patients. Superior to conventional compositions employing either detergents or amino acids in terms of the storage stability of botulinum toxin at 25˜37° C. as well as at refrigerated temperatures, the liquid pharmaceutical composition of the present invention is very useful for storing botulinum toxin under an emergency condition such as an environment without maintaining low temperature.Type: ApplicationFiled: May 20, 2019Publication date: October 3, 2019Inventors: Hyun Ho Jung, Gi Hyeok Yang, Hack Woo Kim, Hee Dong Woo, Chang Hoon Rhee
-
Patent number: 10293034Abstract: Disclosed herein is a liquid pharmaceutical composition of botulinum toxin which is improved in stability. It comprises botulinum toxin, polysorbate 20, and methionine and optionally isoleucine. Employing, instead of the animal-derived protein albumin or gelatin, a combination of polysorbate 20 and methionine and optionally isoleucine as botulinum toxin stabilizers, the liquid pharmaceutical composition eliminates the risk of contaminating the body with serum-derived pathogens or microorganisms and can be administered safely to the body. Also, the composition is convenient for use as a direct injection for patients. Superior to conventional compositions employing either detergents or amino acids in terms of the storage stability of botulinum toxin at 25˜37° C. as well as at refrigerated temperatures, the liquid pharmaceutical composition of the present invention is very useful for storing botulinum toxin under an emergency condition such as an environment without maintaining low temperature.Type: GrantFiled: December 28, 2015Date of Patent: May 21, 2019Assignee: Medy-Tox, Inc.Inventors: Hyun Ho Jung, Gi Hyeok Yang, Hack Woo Kim, Hee Dong Woo, Chang Hoon Rhee
-
Publication number: 20160206710Abstract: Disclosed herein is a liquid pharmaceutical composition of botulinum toxin which is improved in stability. It comprises botulinum toxin, polysorbate 20, and methionine and optionally isoleucine. Employing, instead of the animal-derived protein albumin or gelatin, a combination of polysorbate 20 and methionine and optionally isoleucine as botulinum toxin stabilizers, the liquid pharmaceutical composition eliminates the risk of contaminating the body with serum-derived pathogens or microorganisms and can be administered safely to the body. Also, the composition is convenient for use as a direct injection for patients. Superior to conventional compositions employing either detergents or amino acids in terms of the storage stability of botulinum toxin at 25˜37° C. as well as at refrigerated temperatures, the liquid pharmaceutical composition of the present invention is very useful for storing botulinum toxin under an emergency condition such as an environment without maintaining low temperature.Type: ApplicationFiled: December 28, 2015Publication date: July 21, 2016Inventors: Hyun Ho Jung, Gi Hyeok Yang, Hack Woo Kim, Hee Dong Woo, Chang Hoon Rhee
-
Publication number: 20160089442Abstract: There are provided a lyophilized preparation of botulinum toxin without a protein stabilizer derived from animals. The lyophilized preparation of botulinum toxin according to the present invention can maintain an activity of botulinum toxin, and also exhibit excellent long-term storage stability even under conditions of high temperature, which may occur when botulinum toxin is stored, delivered, and processed.Type: ApplicationFiled: November 30, 2015Publication date: March 31, 2016Inventors: Hyun Ho Jung, Gi Hyeok Yang, Chang Hoon Rhee, Hack Woo Kim, Sung Bum Kim, Seung Hwan Baek
-
Patent number: 9220780Abstract: Disclosed herein is a liquid pharmaceutical composition of botulinum toxin which is improved in stability. It comprises botulinum toxin, polysorbate 20, and methionine and optionally isoleucine. Employing, instead of the animal-derived protein albumin or gelatin, a combination of polysorbate 20 and methionine and optionally isoleucine as botulinum toxin stabilizers, the liquid pharmaceutical composition eliminates the risk of contaminating the body with serum-derived pathogens or microorganisms and can be administered safely to the body. Also, the composition is convenient for use as a direct injection for patients. Superior to conventional compositions employing either detergents or amino acids in terms of the storage stability of botulinum toxin at 25˜37° C. as well as at refrigerated temperatures, the liquid pharmaceutical composition of the present invention is very useful for storing botulinum toxin under an emergency condition such as an environment without maintaining low temperature.Type: GrantFiled: November 25, 2013Date of Patent: December 29, 2015Assignee: Medy-Tox Inc.Inventors: Hyun Ho Jung, Gi Hyeok Yang, Hack Woo Kim, Hee Dong Woo, Chang Hoon Rhee
-
Patent number: 9198958Abstract: There are provided a lyophilized preparation of botulinum toxin without a protein stabilizer derived from animals. The lyophilized preparation of botulinum toxin according to the present invention can maintain an activity of botulinum toxin, and also exhibit excellent long-term storage stability even under conditions of high temperature, which may occur when botulinum toxin is stored, delivered, and processed.Type: GrantFiled: November 5, 2014Date of Patent: December 1, 2015Assignee: Medy-Tox Inc.Inventors: Hyun Ho Jung, Gi Hyeok Yang, Chang Hoon Rhee, Hack Woo Kim, Sung Bum Kim, Seung Hwan Baek
-
Patent number: 8993268Abstract: Provided are a method of producing Clostridium botulinum toxin by using a media containing plant-derived components, and a method of producing Clostridium botulinum toxin by using a flexible closed container.Type: GrantFiled: July 2, 2008Date of Patent: March 31, 2015Assignee: Medy-Tox Inc.Inventors: Hyun-Ho Jung, Gi-Hyeok Yang, Hack-Woo Kim, Byung-Kook Lee, Young-suk Yoon, Hyung-Pyo Hong
-
Publication number: 20150064166Abstract: There are provided a lyophilized preparation of botulinum toxin without a protein stabilizer derived from animals. The lyophilized preparation of botulinum toxin according to the present invention can maintain an activity of botulinum toxin, and also exhibit excellent long-term storage stability even under conditions of high temperature, which may occur when botulinum toxin is stored, delivered, and processed.Type: ApplicationFiled: November 5, 2014Publication date: March 5, 2015Inventors: Hyun Ho Jung, Gi Hyeok Yang, Chang Hoon Rhee, Hack Woo Kim, Sung Bum Kim, Seung Hwan Baek
-
Patent number: 8920795Abstract: There are provided a lyophilized preparation of botulinum toxin without a protein stabilizer derived from animals. The lyophilized preparation of botulinum toxin according to the present invention can maintain an activity of botulinum toxin, and also exhibit excellent long-term storage stability even under conditions of high temperature, which may occur when botulinum toxin is stored, delivered, and processed.Type: GrantFiled: March 30, 2012Date of Patent: December 30, 2014Assignee: Medy-Tox Inc.Inventors: Hyun Ho Jung, Gi Hyeok Yang, Chang Hoon Rhee, Hack Woo Kim, Sung Bum Kim, Seung Hwan Baek
-
Publication number: 20140161783Abstract: Disclosed herein is a liquid pharmaceutical composition of botulinum toxin which is improved in stability. It comprises botulinum toxin, polysorbate 20, and methionine and optionally isoleucine. Employing, instead of the animal-derived protein albumin or gelatin, a combination of polysorbate 20 and methionine and optionally isoleucine as botulinum toxin stabilizers, the liquid pharmaceutical composition eliminates the risk of contaminating the body with serum-derived pathogens or microorganisms and can be administered safely to the body. Also, the composition is convenient for use as a direct injection for patients. Superior to conventional compositions employing either detergents or amino acids in terms of the storage stability of botulinum toxin at 25˜37° C. as well as at refrigerated temperatures, the liquid pharmaceutical composition of the present invention is very useful for storing botulinum toxin under an emergency condition such as an environment without maintaining low temperature.Type: ApplicationFiled: November 25, 2013Publication date: June 12, 2014Applicant: MEDY-TOX, INC.Inventors: Hyun Ho Jung, Gi Hyeok Yang, Hack Woo Kim, Hee Dong Woo, Chang Hoon Rhee
-
Publication number: 20140086900Abstract: There are provided a lyophilized preparation of botulinum toxin without a protein stabilizer derived from animals. The lyophilized preparation of botulinum toxin according to the present invention can maintain an activity of botulinum toxin, and also exhibit excellent long-term storage stability even under conditions of high temperature, which may occur when botulinum toxin is stored, delivered, and processed.Type: ApplicationFiled: March 30, 2012Publication date: March 27, 2014Applicant: MEDY-TOX INC.Inventors: Hyun Ho Jung, Gi Hyeok Yang, Chang Hoon Rhee, Hack Woo Kim, Sung Bum Kim, Seung Hwan Baek
-
Patent number: 8617568Abstract: Disclosed herein is a liquid pharmaceutical composition of botulinum toxin which is improved in stability. It comprises botulinum toxin, polysorbate 20, and methionine and optionally isoleucine. Employing, instead of the animal-derived protein albumin or gelatin, a combination of polysorbate 20 and methionine and optionally isoleucine as botulinum toxin stabilizers, the liquid pharmaceutical composition eliminates the risk of contaminating the body with serum-derived pathogens or microorganisms and can be administered safely to the body. Also, the composition is convenient for use as a direct injection for patients. Superior to conventional compositions employing either detergents or amino acids in terms of the storage stability of botulinum toxin at 25˜370C as well as at refrigerated temperatures, the liquid pharmaceutical composition of the present invention is very useful for storing botulinum toxin under an emergency condition such as an environment without maintaining low temperature.Type: GrantFiled: May 28, 2008Date of Patent: December 31, 2013Assignee: Medy-Tox, Inc.Inventors: Hyun Ho Jung, Gi Hyeok Yang, Hack Woo Kim, Hee Dong Woo, Chang Hoon Rhee
-
Publication number: 20110091937Abstract: Provided are a method of producing Clostridium botulinum toxin by using a media containing plant-derived components, and a method of producing Clostridium botulinum toxin by using a flexible closed container.Type: ApplicationFiled: July 2, 2008Publication date: April 21, 2011Applicant: MEDY-TOX INC.Inventors: Hyun-Ho Jung, Gi-Hyeok Yang, Hack-Woo Kim, Byung-Kook Lee, Young-suk Yoon, Hyung-Pyo Hong
-
Publication number: 20100291136Abstract: Disclosed herein is a liquid pharmaceutical composition of botulinum toxin which is improved in stability. It comprises botulinum toxin, polysorbate 20, and methionine and optionally isoleucine. Employing, instead of the animal-derived protein albumin or gelatin, a combination of polysorbate 20 and methionine and optionally isoleucine as botulinum toxin stabilizers, the liquid pharmaceutical composition eliminates the risk of contaminating the body with serum-derived pathogens or microorganisms and can be administered safely to the body. Also, the composition is convenient for use as a direct injection for patients. Superior to conventional compositions employing either detergents or amino acids in terms of the storage stability of botulinum toxin at 25˜370 C as well as at refrigerated temperatures, the liquid pharmaceutical composition of the present invention is very useful for storing botulinum toxin under an emergency condition such as an environment without maintaining low temperature.Type: ApplicationFiled: May 28, 2008Publication date: November 18, 2010Applicant: Medy-Tox IncInventors: Hyun Ho Jung, Gi Hyeok Yang, Hack Woo Kim, Hee Dong Woo, Chang Hoon Rhee